Sutro Biopharma, Inc. — Operating Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/5dbc3d1b-ed0c-49ba-be19-847fee250f36/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-158.4M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-119873 |
| FY 2024 | $-238.5M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-038884 |
| FY 2023 | $-89.3M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-035949 |
| FY 2022 | $-128.9M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-010976 |
| FY 2021 | $-98.5M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002312 |
| FY 2020 | $-71.1M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-013945 |
| FY 2019 | $-55.5M | 2019-01-01 – 2019-12-31 | evidence 0001564590-20-010890 |
| FY 2018 | $-37.2M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-010253 |
| FY 2017 | $-19.3M | 2017-01-01 – 2017-12-31 | evidence 0001564590-19-010253 |
| FY 2016 | $1.4M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-010253 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).